Initial public offering of Y-mAbs Therapeutics, Inc. (US) on NASDAQ Global Select Market — USD 96 million

Carnegie acted as Nordic selling agent in the initial public offering of Y-mAbs Therapeutics on NASDAQ Global Select Market. Y-mAbs is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. September 2018.